Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Interest Expenses: 2010-2025

Historic Interest Expenses for China Pharma Holdings (CPHI) over the last 16 years, with Sep 2025 value amounting to $6,798.

  • China Pharma Holdings' Interest Expenses fell 0.66% to $6,798 in Q3 2025 from the same period last year, while for Sep 2025 it was $27,166, marking a year-over-year increase of 111.70%. This contributed to the annual value of $27,353 for FY2024, which is 10.53% down from last year.
  • Per China Pharma Holdings' latest filing, its Interest Expenses stood at $6,798 for Q3 2025, which was up 0.28% from $6,779 recorded in Q2 2025.
  • China Pharma Holdings' Interest Expenses' 5-year high stood at $333,441 during Q4 2021, with a 5-year trough of -$252,776 in Q4 2023.
  • In the last 3 years, China Pharma Holdings' Interest Expenses had a median value of $6,843 in 2024 and averaged $7,117.
  • As far as peak fluctuations go, China Pharma Holdings' Interest Expenses skyrocketed by 208.90% in 2021, and later slumped by 362.83% in 2023.
  • Quarterly analysis of 5 years shows China Pharma Holdings' Interest Expenses stood at $333,441 in 2021, then crashed by 71.16% to $96,175 in 2022, then tumbled by 362.83% to -$252,776 in 2023, then surged by 102.69% to $6,802 in 2024, then fell by 0.66% to $6,798 in 2025.
  • Its last three reported values are $6,798 in Q3 2025, $6,779 for Q2 2025, and $6,787 during Q1 2025.